G1 Therapeutics Inc Stock News

* Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China  * G1 to receive $14 million upfront payment, sales roya

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) * ABIOMED, Inc. (NASDAQ: ABMD) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Bio-Rad Laboratories, Inc. Class B Co

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) Bio-Rad Laboratories,...

\- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan RESEARCH TRIANGLE P

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under

VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company

GTHX should submit an NDA for its Trilaciclib that, if approved, could generate $500MM-$1Billion in revenues/year in small-cell lung cancer (69,000 patients wor

G1 Therapeutics Inc (NASDAQ:GTHX)’s share price rose 1.5% during trading on Monday . The company traded as high as $23.77 and last traded at $24.09, approximately 16,651 shares traded hands during t

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued to investors on Monday, AnalystRatings.com report

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, and Genor Biopharma Co. Inc., a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune

Two Sigma Investments LP grew its position in G1 Therapeutics Inc (NASDAQ:GTHX) by 81.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 121